Docetaxel treatment of HT-29 colon carcinoma cells reinforces the adhesion and immunocytotoxicity of peripheral blood lymphocytes in vitro

International Journal of Oncology

Volumn 12, Issue 4, 1998, Pages 957-963

  Grünberg, Elke ^a   Eckert, Klaus ^a   Maurer, H Rainer ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Adhesion; Differentiation induction; Docetaxel; HT 29 colon carcinoma cells; Immunocytotoxicity; Lymphocytes

Indexed keywords

BETA1 INTEGRIN; CD15 ANTIGEN; DOCETAXEL; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MICROSOMAL AMINOPEPTIDASE; VERY LATE ACTIVATION ANTIGEN 5; VERY LATE ACTIVATION ANTIGEN 6;

ARTICLE; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOTOXICITY; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL;

EID: 0031889918     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.4.957     Document Type: Article

References (29)

1. Khayat D: Docetaxel (Taxotere©). Anticancer Drugs 6: 5-6, 1995.
2. Ringel I and Horwitz SB: Studies with RP 56976 (taxotere), a new semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1991.
3. Maurer HR, Eckert K and Bissery MC: Taxotere inhibits the proliferation and induces cell differentiation of HL-60 and K562 human myeloid leukemia cells in vitro. Int J Oncol 3: 161-165, 1993.
4. Kanrantanis E, Nicholson S and Morris DL: Taxotere inhibits In vitro growth of human colonic cancer cell lines. Eur J Surg Oncol 20: 653-657, 1994.
5. Leung MF and Sartorelli AC: The effects of microtubule disrupting drugs on differentiation on HL-60 leukemia cells. Leukemia Res 16: 929-935, 1992.
6. Kinsella AR, Lepts GC, Hill CL and Jones M: Reduced E-cadherin expression correlates with increased invasiveness in colorectal cell lines. Clin Exp Metastasis 12: 335-342, 1994.
7. Wiggers T, Arends JW, Verstijnen C, Moerkerk PM and Bosman FT: Prognostic significance of CEA immunreactivity patterns in large bowel carcinoma tissue. BrJ Cancer 54: 409-414, 1989.
8. Eckert K, Fuhrmann-Selter T and Maurer HR: Docetaxel enhances the expression of E-cadherin and carcinoembryonic antigen (CEA) on human colon cancer cell lines in vitro. Anticancer Res 17: 7-12, 1997.
9. Blottiere HM, Zennadi R, Gregoire M, Aillet G, Denis MG, Meflah K and Le Pendu J: Analysis of the relationship between stage of differentiation and NK/LAK susceptibility of colon carcinoma cells. Int J Cancer 53: 409-417, 1993.
10. Rivoltini L, Cattoretti G, Arienti F, Mastroianni A and Parmiani G: CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes. Int J Biol Markers 7: 143-147, 1992.
11. Rivoltini L, Cattoretti G, Arienti F, Mastroianni A, Melani C, Colombo MP and Parmiani G: The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer 47: 746-754, 1991.
12. Quillet-Mary A, Cavarec L, Kermarrec N, Marchiol-Foumigault C, Gil ML, Conjeaud H and Fradelizi D: Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets. Int J Cancer 47: 473-479, 1991.
13. Blottièrc HM, Burg C, Zennadi R, Perrin P, Blanchardie P, Bara J, Mcflah K and le Pendu JL: Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity. Int J Cancer 52: 609-618, 1992.
14. Rousset M: The human colon carcinoma cell lines HT-29 and Caco-2: two in vitro models for the study of intestinal differentiation. Biochemie 68: 1035-1040, 1986.
15. Friedmann J, Seger M, Levinsky H and Allalouf D: Modulation of carcinoembryonic antigen release by HT-29 colon carcinoma line in the presence of different agents. Experientia 43: 1121-1122, 1987.
16. Garbin F, Eckert K and Maurer HR: Evaluation of the MTT and SRB assay for testing LAK cell mediated growth inhibition of various adherent and nonadherent tumor target cells. Immunol Methods 170: 269-271, 1994.
17. Gohla A, Eckert K and Maurer HR: A rapid and sensitive fluorometric screening assay using YO-PRO-1 to quantify tumor cell invasion through Matrigel. Clin Exp Metastasis 14: 451-458, 1996.
18. Robertson MJ, Caligiuri MA, Manley TJ, Levine H and Ritz J: Human natural killer cell adhesion molecules. J Immunol 145: 3194-3201, 1990.
19. Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI and Moretta L: The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoconal-antibody-target T lymphocytes. Int J Cancer 56: 846-852, 1994.
20. Kammerer R and Kleist S: CEA expression of colorectal adenocarcinomas is correlated with their resistance against LAK-cell lysis. Int J Cancer 57: 341-347, 1994.
21. Grünberg E, Eckert K and Maurer HR: Prothymosin α1 enhances the interleukin-2 activated killer cell adhesion to and immunocytotoxicity against Docetaxel-treated HT-29 colon carcinoma cells in vitro. Int J Thymology (In press).
22. Kvale D, Krajci P and Brandtzaeg P: Molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines. Scand J Immunol 35: 669-676, 1992.
23. Herrlich P, Zöller M, Pals ST and Ponta H: CD44 splice variants: metastases meet lymphocytes. Immunol Today 14: 395-399, 1993.
24. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I and Tsuruo T: Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CDI3. Clin Exp Metastasis 13: 337-344, 1995.
25. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M and Kannagi R: Contribution of carbohydrate antigens sialyl Lewis A and sialyl lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53: 354-361, 1993.
26. MacKay CR, Terpe HJ, Stauder R, Marston WL, Stark H and Gunthert U: Expression and modulation of CD44 variant isoforms in human. J Cell Biol 124: 71-82, 1994.
27. Wielensa VJM, Heider KH, Offerhaus GJH, Adolf GR, van den Berg FM, Ponta H, Herrlich P and Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754-4756, 1993.
28. Perrin P, Cassagnau E, Burg C, Patry Y, Vavasseur F, Harb J, Le Pendu J, Douillard J-Y, Galmiche J-P, Bornet Fand Meflah K: An interleukin-2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology 107: 1697-1708, 1994.
29. Sternberg CN, Ten Bokkel Huinik WW, Smyth JF, Bruntsch U, Dirix LY, Pavlidis NA, Franklin H, Wanders S, le Bail N and Kaye SB: Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC early clinical trial group study. Br J Cancer 70: 376-379, 1994.